Presentation of new data of antimicrobial effects on multi-drug resistant bacterial infections from Ukraine war victims

CXCL12-expressing Limosilactobacillus reuteri has clinically relevant antimicrobial effects of multidrug-resistant bacteria isolated from wounds of war victims in Ukraine Presented by Dr Andreas Fasth Poster ID 939

One PhD Position in chemokine immunobiology - HORIZON-MSCA-2022-DN Doctoral Network “B-ACTIVE”

Ilya Pharma gives an update at Pharmabiotics in Lille, France March 13-15

Ilya Pharma presents at Biologics World Nordic in Copenhagen March 6-7

Ilya Pharma presents at Uppsala University Pharmaceutical Science Day 1st February in Uppsala

Ilya Pharma receives funding by HORIZON Marie Sklodowska-Curie Doctoral Network B-ACTIVE

Ilya Pharma is attending the 42nd Annual J.P. Morgan Healthcare Conference in SF 8-11 Jan

Seminar at SciLifeLabs by Professor Neil Forbes - pioneer of genetically modified bacteria for treatment of solid tumors

Today there are >20 drug candidates that are genetically modified bacteria have been or are evaluated in clinical trials in a wide range of medical indications.

Nailing of a Doctoral Thesis

"Promoting healing of skin and mucosa by immunomodulation using CXCL12 producing lactic acid bacteria: From bench to bedside" by Industrial PhD student Emelie Öhnstedt.

Ilya Pharma is participating in the Jefferies Healthcare Conference in London, Nov 14-16

Interested in learning more about Ilyas's ILP-technology, local-acting immunotherapies or any of the trials SITU-SAFE, SITU-SURGERY, SITU-HEAL or SITU-GUT or our recent work in AMR and meet our CEO Evelina Vågesjö, please reach out.